FindTrial
Sign In

Semorinemab

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Alzheimer's Disease

Phase 2

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
TerminatedNCT03289143
Genentech, Inc.Alzheimer's Disease
Start: 2017-10-04End: 2021-01-15Updated: 2022-03-16
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
CompletedNCT03828747
Genentech, Inc.Alzheimer's Disease
Start: 2019-01-25End: 2023-08-30Updated: 2024-09-24

Related Papers

CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures.
2026-01-01
Cerebrospinal fluid MTBR243 tau correlates with [18F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures
Alzheimer s & Dementia2025-12-01
Development and validation of speech‐based biomarkers for measuring clinical progression in AD clinical trials
Alzheimer s & Dementia2025-12-01
Formal and Informal Care Utilization in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease: Cross-Sectional and Longitudinal Analyses of RUD-Lite Data from the Tauriel Study.
2025-11-25
The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.
2025-07-01
Robustness and generalizability of a speech‐based digital biomarker derived from recordings of the Clinical Dementia Rating (CDR) interview
Alzheimer s & Dementia2024-12-011 citations
Deriving meaningful within‐patient change thresholds for the ADCS‐ADL in trials of early and mild‐to‐moderate Alzheimer’s disease ‐ a caregiver‐rated, anchor‐based analysis of the Tauriel and Lauriet trials
Alzheimer s & Dementia2024-12-01
Impact of Study Partner Type on Participant Retention Across Global Regions in the Tauriel and Lauriet Trials for Alzheimer’s Disease
Alzheimer s & Dementia2024-12-01
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
Alzheimer s & Dementia2024-11-089 citations
Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease
Alzheimer s & Dementia2024-07-179 citations
Evaluation of partial volume correction and analysis of longitudinal [18F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models
Frontiers in Neuroimaging2024-03-281 citations
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
2024-02-2216 citations
18F GTP1 Tau PET image‐derived features improve the prediction of CDR‐SB progression in a multi‐modal model in prodromal to moderate AD
Alzheimer s & Dementia2023-12-01
Formal and informal healthcare utilization in MCI and mild dementia due to AD: Cross‐sectional and longitudinal analyses of RUD‐Lite data from the Tauriel Study
Alzheimer s & Dementia2023-12-01
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Neurology2023-08-2994 citations
Cross‐sectional and longitudinal assessments of function in prodromal‐to‐mild Alzheimer's disease: A comparison of the ADCS‐ADL and A‐IADL‐Q scales
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring2023-04-0110 citations
Evaluation of Longitudinal [18F]GTP1 Tau Burden Metrics in the Tauriel Phase II Study
Alzheimer s & Dementia2022-12-01
Selecting appropriate meaningful change thresholds for trials of early (prodromal‐to‐mild) AD: A caregiver‐rated, anchor‐based analysis based on the Tauriel Study
Alzheimer s & Dementia2022-12-01
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease
JAMA Neurology2022-06-13171 citations
Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease.
2021-12-0120 citations

5 more papers not shown